{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+90&page=2", "query": { "intervention": "Tacrolimus 90", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+90&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T20:26:30.101Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03663933", "title": "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Primary T-cell Immunodeficiency Disorders", "Immune System Diseases", "Common Variable Immunodeficiency" ], "interventions": [ { "name": "e-ATG", "type": "DRUG" }, { "name": "Immunosuppression Only Conditioning", "type": "PROCEDURE" }, { "name": "Reduced Intensity Conditioning", "type": "PROCEDURE" }, { "name": "GVHD Prophylaxis", "type": "DRUG" }, { "name": "Allogeneic HSC", "type": "PROCEDURE" }, { "name": "Bisulfan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "PFTs", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspirate & Biopsy", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "2D ECHO", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 71, "start_date": "2018-09-04", "completion_date": "2030-04-03", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663933" }, { "nct_id": "NCT04205240", "title": "Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Srinivas Devarakonda", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2020-12-22", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04205240" }, { "nct_id": "NCT03388008", "title": "Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Transplant Rejection", "Antibody-mediated Rejection" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 27, "start_date": "2019-12-17", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2022-11-25", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 2, "location_summary": "St Louis, Missouri • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03388008" }, { "nct_id": "NCT00765661", "title": "Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure", "Renal Failure" ], "interventions": [ { "name": "Tacrolimus (Tacro™)", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765661" }, { "nct_id": "NCT01342289", "title": "Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Lymphoma", "Leukemia", "Myelodysplastic Syndrome(MDS)", "Multiple Myeloma", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus 60", "type": "DRUG" }, { "name": "Tacrolimus 90", "type": "DRUG" }, { "name": "Tacrolimus 120", "type": "DRUG" }, { "name": "Bone marrow transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Months to 75 Years" }, "enrollment_count": 127, "start_date": "2011-08", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342289" }, { "nct_id": "NCT06828796", "title": "Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Disease and Disorders", "Hematopoietic Cell Transplant" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycofenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2025-07-03", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06828796" }, { "nct_id": "NCT04127721", "title": "Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allogeneic Stem Cell Transplant Recipient", "Hematologic and Lymphocytic Disorder", "Hematopoietic and Lymphoid Cell Neoplasm" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2020-09-22", "completion_date": "2020-09-22", "has_results": false, "last_update_posted_date": "2020-10-29", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04127721" }, { "nct_id": "NCT00709592", "title": "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia", "Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Thymoglobulin", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic PBSCT or BMT", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE", "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2008-07-21", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709592" }, { "nct_id": "NCT01572662", "title": "Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Myeloproliferative Diseases", "Non-Hodgkins Lymphoma", "Hodgkins Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Fludarabine monophosphate", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "5 Years to 75 Years" }, "enrollment_count": 201, "start_date": "2012-04-11", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01572662" }, { "nct_id": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia" ], "interventions": [ { "name": "ARA-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Campath-1H", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplantation", "type": "OTHER" }, { "name": "Total body radiation (TBI)", "type": "RADIATION" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adback NK or T Cell", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 22, "start_date": "2007-09", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-09-26T20:26:30.101Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536978" } ] }